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Urokinase-type plasminogen activator (uPA) regulates angio-
genesis and vascular permeability through proteolytic degrada-
tion of extracellular matrix and intracellular signaling initiated
upon its binding to uPAR/CD87 and other cell surface recep-
tors. Here, we describe an additional mechanism by which uPA
regulates angiogenesis. Ex vivo VEGF-induced vascular sprout-
ing from Matrigel-embedded aortic rings isolated from uPA
knock-out (uPA/) mice was impaired compared with vessels
emanating from wild-type mice. Endothelial cells isolated from
uPA/mice show less proliferation and migration in response
to VEGF than their wild type counterparts or uPA/ endothe-
lial cells inwhich expression ofwild type uPAhadbeen restored.
We reported previously that uPA is transported from cell sur-
face receptors to nuclei through a mechanism that requires its
kringle domain. Intranuclear uPAmodulates gene transcription
by binding to a subset of transcription factors. Here we report
that wild type single-chain uPA, but not uPA variants incapable
of nuclear transport, increases the expression of cell surface
VEGF receptor 1 (VEGFR1) and VEGF receptor 2 (VEGFR2) by
translocating to the nuclei of ECs. Intranuclear single-chain
uPA binds directly to and interferes with the function of the
transcription factor hematopoietically expressed homeodo-
main protein or proline-rich homeodomain protein (HHEX/
PRH), which thereby lose their physiologic capacity to repress
the activity of vehgr1 and vegfr2 gene promoters. These studies
identify uPA-dependent de-repressionof vegfr1 and vegfr2 gene
transcription through binding to HHEX/PRH as a novel mech-
anism by which uPA mediates the pro-angiogenic effects of
VEGF and identifies a potential new target for control of patho-
logic angiogenesis.
In the healthy adult blood vessels show little or no growth
or extension except during the ovarian cycle and during pla-
cental development, and there is minimal physiologic turn-
over of vascular endothelial cells (1). Angiogenesis, the pro-
cess by which new blood vessels develop from pre-existing
vasculature, is activated by diverse pathophysiological stim-
uli, such as hypoxia, inflammation, or wounding, and the
vessels return to the quiescent state once these stimuli are
removed or wound closure has been attained (1, 2). These
complex processes of physiological and adaptive angiogene-
sis require a finely tuned balance between integrins, angio-
poietins, chemokines, junctional molecules, oxygen sensors,
matrix components, endogenous inhibitors, and many other
factors (3).
However, there are prevalent and important settings
(malignancy, inflammation, diabetic retinopathies, and
development of atherosclerotic plaques, among others) in
which pro-angiogenic stimuli predominate, resulting in
what has been referred to as the “angiogenic switch” (4, 5).
Persistent excessive neoangiogenesis may be deleterious to
the host, e.g. enhancing tumor growth or proliferation of
“leaky” retinal vessels subject to rupture. A more thorough
understanding of the process underlying the angiogenic
switch that are not shared by normal vessels might identify
steps in the process that could be subject to therapeutic
intervention aimed at suppressing excessive neoangiogen-
esis or safely inducing therapeutic angiogenesis.
Early in angiogenesis, endothelial cells divide, migrate,
degrade, and invade abluminal basement membrane forming
and stable vascular tubular structures (2). Urokinase-type plas-
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minogen activator (uPA),3 its high affinity receptor (uPAR;
CD87), and its inhibitor plasminogen activator inhibitor 1
(PAI-1) have been implicated in each of these steps (6–8). Rest-
ing endothelial cells express low levels of uPA and uPAR,
whereas their expression is strongly up-regulated during angio-
genesis (9, 10). uPA promotes pro-angiogenic signaling upon
binding to several interacting surface receptors, including
uPAR (CD87), LDL receptor-related protein receptor (LRP/
2MR), and specific integrins (11–17). uPA also enzymatically
converts plasminogen into the broadly acting serine protease
plasmin (18, 19) that degrades matrix proteins and activates
several matrix metalloproteinases (20–23). uPAR-bound uPA
is typically localized on the leading edge of migrating endothe-
lial and other cells (24–26) where it not only helps to maintain
focused degradation of extracellular matrix but also to liberate
matrix-bound pro-angiogenic growth factors, such as VEGF
(27–29) and basic FGF (bFGF/FGF-2) (30, 31) via plasmin-de-
pendent proteolysis. uPA also directly activates VEGF-A189
through proteolytic cleavage independent of plasmin (32).
uPA has also been implicated in the process through which
VEGF stimulates endothelial cell proliferation and forms new
blood vessels. For example, exogenous VEGF does not induce
angiogenesis when injected into infarcted myocardium in uPA
knock-out mice (uPA/ mice) (33). VEGF-induced endothe-
lial permeability also depends on uPA and uPAR (34). Endothe-
lial cells derived from uPA/ mice do not overexpress the
X-linked inhibitor of apoptosis (XIAP), which maintains endo-
thelial survival in response to VEGF unless uPA is restored (35).
We have also reported that uPA enhances endothelial permea-
bility through intracellular signaling pathways shared with
VEGF (36). However, the possibility that uPA contributes to
VEGF-induced signaling through pathways unrelated to prote-
olysis and receptor-mediated intracellular signaling has not
been explored.
We recently reported that single-chain uPA (scuPA) translo-
cates to the nuclei of proliferating cells (37) where it regulates
transcription factorHOXA5 (38), which is involved in endothe-
lial cell proliferation and repair (39, 40). In this manuscript we
provide insight into a novel mechanism through which uPA
mediates the pro-angiogenic effects of VEGF. We show that
scuPA translocates to the nuclei of endothelial cells where it
binds to the homeobox transcription factor HHEX, a repressor
of vegfr1 and vegfr2 gene promoters, and in doing so interferes
with their function and thereby induces VEGF receptor expres-
sion. These findings delineate a novel mechanism that contrib-
utes to the regulation of endothelial proliferation and a poten-
tial new approach toward control of aberrant angiogenesis.
Experimental Procedures
Vector Constructs
HHEX-FLAG/pcDNA3.1 Constructs—A vector encoding
NLS-mouse nucleolin, described previously (37), was used to
amplify a pcDNA3.1-FLAG fragment to retain FLAGwithin the
pcDNA3.1 vector sequence and introduce Xho1 restriction site
at the 5 end and EcoR1 site at the 3 end using the primers:
forward 5-TGCTGGACGCTCGAGCGACTACAAAGACG-
ATGACGAT-3 and reverse 5-TGCATAGTGAATTC-
CAGCACACTGGCGGCCGT-3.
Full-length HHEX was amplified using the primers P1 (for-
ward) and P2(reverse) to introduce EcoRI and XhoI restriction
sites, respectively (P1, 5-TGCTGGAATTCACTATGCAGT-
ACCCGCACCCCGGGCC-3; P2, 5-GTAGTCGCTCGAGC-
GTCCAGCATTAAAATAGC-3), and cDNA encoding hu-
man HHEX (Thermo/Open Biosystems) was used to amplify
HHEX. The fragment was restricted with EcoR1 and Xho1 and
ligatedwith the pcDNA3.1-FLAG fragment to obtain the vector
encoding HHEX which possesses FLAG tag on the C terminus.
Construction and Expression of Mouse K-uPA Domain
Deletion Mutant—The muPA/pMT/BiP plasmid encoding
mouse uPA inserted between the Bgl2 (5) and Xba1 (3) sites
used to express the recombinantWTmouse uPA inDrosophila
S2 cell-based expression system has been described previously
(41). To obtain a vector that encodes kringle-deficient muPA
(K-muPA), the muPA/pMT/Bip plasmid was used as a tem-
plate, and an overlap PCR strategy was applied. In the first step,
two fragments were generated using the primer sets 1) P1 for-
ward (5-CGCTCGGGAGATCTGGCAGTGTACTTGGAGC-
3) and P2 reverse (5-CTACAGACGAAGAAGGCTTTGC-
ATCTATCTCACAGTGCTkCCCCCTGGAATTTCC-3) to
generate the fragment 1.1, with the Bgl2 restriction site at the 5
end, and 2) P3 forward (5-GGAAATTCCAGGGGGAGCAC-
TGTGAGATAGATGCAAAGCCTTCTTCGTCTGTAG-3)
and P4 reverse (5-CGAAGGGCCCTCTAGACTATTAGAA-
GGCCAGACCTTTCTCTTC-3) to generate the fragment 1.2
having theXba1 restriction site at the 3 end. In the second step,
the 1.1 and 1.2 fragments were mixed at an equimolar ratio,
and the mixture was used as the template for the overlap PCR
using the P1 forward and P4 reverse primers to generate the
K-muPA fragment having the Bgl2 and Xba1 restriction sites
at the 5 and 3 ends, respectively (K-muPA(Bgl2/Xba1) frag-
ment). ThemuPA/pMT/BiP plasmid was cut with the Bgl2 and
Xba1 restriction enzymes to remove the muPA insert, and the
restricted plasmidwas used to ligate theK-muPA(Bgl2/Xba1)
fragment to obtain theK-muPA/pMT/BiP vector. This vector
was then used to express the recombinant K-muPA lacking
amino acids 48–144 in theDrosophila S2 cell-based expression
system as described (42).
muPA/pWPXL and K-muPA/pWPXL Constructs—The
QuikChange mutagenesis kit (Stratagene) and muPA/pMT/
BiP plasmid template were used to replace the BiP signal pep-
tide in the muPA-pMT/BiP construct with the native signal
peptideMKVWLASLFLCALVVKNSEG for mouse uPA in two
steps. First, a pair of primers (P5 forward (5-TTGGCCTCTC-
GCTCGGGAGATCTTGCGCCTTGGTGGTGAAAAACTC-
TGAAGGTGGCAGTGTACTTGGAGCTCCTGATGAA-3)
and P6 reverse (5-TTCATCAGGAGCTCCAAGTACACTG-
CCACCTTCAGAGTTTTTCACCACCAAGGCGCAAGAT-
CTCCCGAGCGAGAGGCCAA-3)) was used to replace the
nucleotide sequence encoding the BiP signal sequence for the
nucleotide sequence encodingCALVVKNSEGpeptide at the 5
3 The abbreviations used are: uPA, urokinase-type plasminogen activator;
uPAR, uPA receptor; scuPA, single-chain uPA; GFD, growth factor-like
domain; Ab, antibody; MVEC, microvascular endothelial cell; hMVEC,
human MVEC; LMVEC, lung MVEC; mLMVEC, mouse LMVEC; PRH, proline-
rich homeodomain protein; EC, endothelial cell; con, control; muPA,
mouse uPA; ATF, amino-terminal fragment; SM, smooth muscle.
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end of the sequence encoding muPA (muPA/pMT/sign1 inter-
mediate vector). Second, the primer pair (P7 forward (5-GTT-
GGCCTCTCGCTCGGGAGATCTATGAAAGTCTGGCT-
GGCG AGCCTGTTCCTCTGCGCCTTGGTGGTGAAA-
AACTCTG-3)) and P8 reverse (5-CAGAGTTTTTCAC-
CACCAAGGCGCAGAGGAACAGGCTCGCCAGCCAGAC-
TTTCATAGATCTCCCGAGCGAGAGGCCAAC-3)) was used
to introduce the sequence encoding the MKVWLASLFL
peptide into the muPA/pMT/sign2 intermediate vector, which
encodes full-length mouse uPA with native signal peptide
allowing the protein to be secreted in mammalian cells. The
following primer pair (P9 forward (5-GCCTAAGCTTACGC-
GTATGAAAGTCTGGCTGGCG-3) and P10 reverse (5-
GTAATCCAGAGGTTGATTATCATATGACTAGTCTAT-
TAGAAGGCCAGACCTTTCTC-3)) was used to amplify the
fragment muPA with the natural signal peptide from the
muPA/pMT/sign2 intermediate vector template to introduce
an MluI site in the 5-untranslated region and an SpeI site in
the 3-untranslated region of the fragment, respectively. The
fragment was cut with the Mlu1 and Spe1 restriction enzymes
and then cloned into the pWPXL vector (Addgene and D.
Trono laboratory, EPFL-SV-GHI-LVG, Station 19, CH-1015,
Lausanne, Switzerland) and digested with MluI and SpeI to
obtain the muPA/pWPXL lentiviral transfer vector, which
encodes full-length mouse uPA.
To obtain the pWPXL-based lentiviral transfer vector, which
encodesK-muPA, themuPA/pMT/sign2 intermediate vector
was used as a template, and an overlap PCR strategywas applied
as described above. The P9 forward primer (5-GCCTAAGC-
TTACGCGTATGAAAGTCTGGCTGGCG-3) and the P2
reverse primer (5-CTACAGACGAAGAAGGCTTTGCATC-
TATCTCACAGTGCTCCCCCTGGAATTTCC-3) were used
to generate the fragment 2.1, having theMlu1 restriction site at
the 5 end. The P3 forward primer 5-GGA AAT TCC AGG
GGG AGC ACT GTG AGA TAG ATG CAA AGC CTT CTT
CGT CTG TAG-3 and the P10 reverse primer 5-GTAATCC-
AGAGGTTGATTATCATATGACTAGTCTATTAGAAGG-
CCAGACCTTTCTC-3 were used to generate the fragment
2.2 having the Spe1 restriction site at the 3 end. As above, the
mixture of 2.1 and 2.2 fragments was used as the template for
the overlap PCR using the P9 forward and P10 reverse primers
to generate the K-muPA fragment having the Mlu1 and Spe1
restriction sites at the 5 and 3 ends, respectively. This vector
was treated with the above restriction enzymes and cloned in
pWPXL vector as above to generate K-muPA/pWPXL. Pro-
duction of lentivirus using empty pWPXL and muPA/pWPXL
or K-muPA/pWPXL as transfer vectors was performed as
described previously (41)
Animals
uPA/ and WT mice were obtained under a Material
Transfer Agreement (MTA) between the Russian Cardiology
Research and Production Center (Moscow, Russia) and the
FIRC Institute for Molecular Oncology (Milan, Italy). The col-
ony wasmaintained at the Pushchino nursery (Pushchino, Rus-
sia). All experimental procedures were performed according to
the “Rules for carrying out experiments using laboratory ani-
mals” of the Russian Cardiology Research and Production
Center.
Isolation ofMouse LungMicrovascular Endothelial Cells
(mLMVECs)
Mouse pulmonary microvascular endothelial cells were iso-
lated as described (43) with minor modifications. Lung tissue
obtained from 6–8-day-old WT and uPA/mouse pups was
cut into pieces, digestedwith collagenase II/dispase (C/D) solu-
tion, and dispersed mechanically into single-cell suspensions.
Lung microvascular endothelial cells (LMVECs) were purified
from the cell suspension using positive selection with anti-
mouse CD31 (PECAM-1) antibody MicroBeads Kit (MACS
Miltenyi Biotec, catalog #130-097-418, Lot 5130819199). Cells
were further purified using Dynabeads coupled to anti-mouse
ICAM-2 antibody (Southern Biotech, catalog #1925-01, Lot
F1912-YD13). The resultant mLMVECs exhibited a cobble-
stone phenotype, as visualized by phase-contrast light
microscopy, and their endothelial phenotype was confirmed
by fluorescence microscopy using anti-mouse CD31 anti-
body (BioLegend, catalog #102402, lot B128572).
Migration Assay
mLMVECs isolated from WT or uPA/ mice or uPA/
mLMVECs infected with control or mouseWT uPA- ormouse
K-uPA-encoding LVs were deprived for 24 h in EBM-2 basal
medium supplemented with 0.5% FBS (EBM-2/0.5% FBS
medium). Starved cells were detached by trypsin, washed, and
resuspended in EBM-2/0.5% FBS. Wells in 24-well plates were
filledwith either EBM-2/0.5%FBSor EBM-2/0.5%FBSmedium
supplemented with 25 ng/ml mouse VEGF A (R&D Diagnos-
tics). FluoroBlokTM transwell inserts (BD Biosciences) were
inserted into the wells, and cell suspensions, prepared as above
(5 104 cells/ml), were added to the transwells and allowed to
migrate for 18 h per the manufacturer’s instructions. No
increase in total cell number was observed during this time (not
shown). Migrating cells were loaded with Calcein AM dye and
Hoechst33342 dye for visualization and fixed in 4% paraformal-
dehyde. Cells were photographed using either a Leica DM4000
inverted fluorescence microscope equipped with a 10 objec-
tive or with an EVOS FL Auto Cell Imaging System (Thermo-
Fisher Scientific) using a 4 objective. Cell numbers in each
microscopic field were quantified using EVOS software.
In Vitro Endothelial Cell Tube Formation Assay
mLMVECs isolated from WT or uPA/ mice or uPA/
mLMVECs infected with control or mouseWT uPA- ormouse
K-uPA-encoding LVs were studied. In vitro endothelial cell
tube formation assay was performed and quantified as
described by us previously (44–46). Movies showing time
courses of endothelial tube network formation by WT and
uPA/mouse ECs were taken using the EVOS FL Auto Cell
Imaging System equipped with the EVOSOnstage Incubator.
Ex Vivo Aortic Sprouting
Thoracic aortae were isolated from 8–12-week-old mice as
described by us previously (47, 48). Aortic segments were
embedded into Matrigel (Corning) containing EGM with
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VEGF (5 nM). Aortic ring sprouts on days 7 or 10 were fixed in
4% paraformaldehyde and photographed as below. In some
experiments the samples were stained with DAPI and photo-
graphed to include all sprouts along the perimeter of the pro-
jection of the vessel ring and the entire length of the sprouts.
Sprout lengths were determined by morphometric analysis
using ImageJ software. To determine the entire area occu-
pied by sprouts, several fluorescent images of the same vessel
ring taken at different positions were superimposed and
stitched to reconstruct the entirety of the vessel including
the outgrown sprouts. Sprout areas were determined by
morphometric analysis using ImageJ software and dividing
the area of the sprouts by the aortic perimeter. Images of
sprouting were obtained using an EVOS FL Auto Cell Imag-
ing System with a 4 objective or a Leica DMI6000 micro-
scope using a 5 objective.
Proteins and Purification
Recombinant human wild type human scuPA (WT-scuPA),
scuPA lacking the growth factor-like domain (GFD) (GFD-
scuPA, amino acids 47–411), scuPA lacking the Kringle
domain (KD) (lacking amino acids 47–135; K-scuPA), the
N-terminal fragment of uPA, amino-terminal fragment (ATF)
(GFD  KD, amino acids 1–143), and low molecular weight
scuPA (amino acids 144–411) were expressed using the Dro-
sophila Expression System (Invitrogen) in Schneider S2 cells
and purified as described (42).
Immunoprecipitation andWestern Blotting
HEK293 cells were transfected with HHEX-FLAG/
pcDNA3.1 and uPA/pcDNA3.1 vectors as described (38). Two
days after transfection, cells were harvested, and nuclear
extracts were prepared using the Novagen NucBuster Protein
Extraction kit. uPA and/orHHEX-FLAGwere immunoprecipi-
tated using anti-uPA mouse mAbs (IMTEK, catalog #MGH
Upai) or mouse anti-FLAG mAbs (Sigma, catalog #F1804, Lot
124K6106) immobilized on agarose beads. Immunoprecipi-
tated proteins were subjected to Western blot analysis. Im-
munoprecipitated and co-immunoprecipitated uPA and/or
HHEX-FLAG were detected using anti-uPA rabbit polyclonal
Abs (American Diagnostica, catalog #389, Lot 198) and mouse
HRP-conjugated anti-FLAGM2mAbs (Sigma, catalog #A8592,
Lot 013K9167). Human LMVEC were pretreated with recom-
binant scuPA to allow translocation to the nucleus. Nuclear
extracts were obtained as described above. uPA and endoge-
nous HHEX were immunoprecipitated using anti-uPA mouse
mAbs (as above) and anti-HHEXmousemAbs (SantaCruz Bio-
technology, catalog #sc-81284, Lot E2015). uPAwas detected as
above. HHEX was detected using rabbit anti-HHEX Abs
(Abcam, catalog #34222, Lot 513969).
Western blot analysis of the cell lysates was performed as
described elsewhere using the following antibodies (Abs): anti-
phospho(Thr-202/Tyr-204)Erk1,2 (catalog #4370, Lot 6), anti-
Erk1,2 (catalog #4695, Lot 14), anti-phospho(Ser-235/236)S6 (cat-
alog #4856, Lot 9), anti-S6, (catalog #2217, Lot 5) from Cell
Signaling Technology, anti-VEGFR1 (catalog #32152, Lot
GR140909-3) and anti-VEGFR2 (catalog #39256, Lot
GR129356-1) from Abcam, and anti-GAPDH (catalog
#MAB374, Lot JC1641540) from Millipore.
Transcription Factor Protein Binding Array Analysis
Binding of uPA to transcription factors was analyzed using
the TranSignalTM TF Protein Array kit (Version I, catalog
#MA3501, Panomics) per the manufacturer’s instructions as
described by us previously (38). Imaging of themembranes was
performed using the ChemiDoc-It Imaging System (UVP,
LLC, Upland, CA) with the LabWorks Image Acquisition and
Analysis Software (UVP Inc. Bioimaging Systems).
Indirect Immunofluorescence Staining
To analyze the intracellular distribution of exogenously
added uPAs in primary humanpulmonarymicrovascular endo-
thelial cells (hLMVECs), the cells were grown in 8-well cham-
ber slides (LabTek, Campbell, CA) and incubated with 20 nM
WT-scuPA orGFD-scuPA orK-scuPA for 30min. The cells
were stained as described (37) using the anti-uPA Abs (Ameri-
can Diagnostica, catalog #389, Lot 198), and nuclei were coun-
terstained with DAPI (0.5 g/ml). Stained cells were mounted
as described (37) and examined with a confocal laser-scanning
microscope (Zeiss LSM 510; Carl Zeiss, Heidelberg, Germany).
Images taken in DAPI channel were pseudocolored in red.
Immunohistochemistry Analysis
Paraffin-embedded sections of non-small lung carcinoma
tissue were deparaffinized in xylene and rehydrated in graded
ethanol solutions. Blocking of endogenous peroxidase and per-
meabilization was performed in 2.2% H2O2 solution in metha-
nol. Permeabilized sections were blocked for 20 min using 10%
horse serum diluted in 1% BSA/1 automation buffer solution
(blocking buffer) at room temperature. Sections were incu-
bated overnight at 4 °C with primary mouse monoclonal anti-
human uPA Ab (American Diagnostica, catalog #3689, Lot
060406) diluted in the blocking buffer, washed, and incubated
with biotinylated horse anti-mouse secondary Ab diluted in the
blocking buffer for 30 min at 37 °C followed by incubation with
streptavidin-HRP (Vectastain kit; Vector). The tyramide signal
amplification (TSA) reaction was performed using Alexa 488
Fluor TSA kit (Invitrogen) as per the manufacturer’s instruc-
tions. Tissue sections were then incubated with Cy3-conju-
gated mouse monoclonal anti-SM -actin Ab (Sigma, catalog
#C6198, Lot 024M4838V) in blocking buffer for 1 h. The slides
were incubated with SYTO-6 fluorescent dye (Invitrogen) to
visualize the nuclei, mounted in Gel-Mount medium (Electron
Microscopy Sciences, Hatfield, PA), and analyzed using confo-
cal microscopy, as above. Images taken in far-red channel for
nuclear staining (SYTO-6 stain) were pseudo-colored in red.
Images taken in red channel (Cy3-conjugated anti-SM -actin)
were pseudocolored in blue.
Immunohistochemical staining of sections was performed
for the endothelial cell marker von Willebrand factor. Fresh
specimen sections and de-mounted sections previously stained
for uPA and SM -actin were subjected to antigen retrieval
using Dako Target Retrieval Solution after blocking of endoge-
nous peroxidase as above. Sections were blocked using 10%
goat serum diluted in 1% BSA/1 automation buffer and incu-
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bated overnight at 4 °C with primary rabbit polyclonal anti-
von Willebrand factor Ab (Dako, catalog #A008229–5, Lot
20020455) or whole rabbit Ig as a negative control. Subsequent
staining steps were as above except that 3,3-diaminobenzidine
(Thermo Fisher) was used as anHRP substrate, and nuclei were
counterstained with hematoxylin solution (Thermo Fisher).
Images were taken using EVOS FL Auto Imaging System.
Solid Phase Protein-Protein Binding Assay
To study HHEX-FLAG binding to uPA deletion mutants,
96-well plates were coated with 0.7 M each of recombinant
uPA deletion mutant or 1% BSA in Dulbecco’s modified PBS,
blocked with Dulbecco’s modified PBS supplemented with 1%
BSA, and incubatedwith the nuclear extract from293HEK cells
transfected with the HHEX-FLAG-pcDNA3.1 construct for
1 h.AfterwashingwithDulbecco’smodified PBS supplemented
with 1% BSA, bound HHEX-FLAG was detected using anti-
HHEX rabbit polyclonal Ab (Abcam, catalog #34222 Lot
513969) followed by incubationwithHRP-conjugated anti-rab-
bit antibody (Jackson ImmunoResearch Laboratories, catalog
#111-035-144) and color development with 3,3,5,5-tetrameth-
ylbenzidine. The reaction was terminated by adding 1 mM
H2SO4, and the absorbance at 450 nm was measured using a
microplate reader.
Cell Proliferation Assay
Proliferation of human LMVECs (Lonza) was measured
using the [3H]thymidine incorporation assay as described (49).
Briefly, cells were plated at 60% confluency in EGM-2 complete
medium (Invitrogen), starved in EBM-2 medium containing
0.5% FBS and antibiotic/antimycotic supplement (EBM-2/0.5%
FBS) (Invitrogen) for 24 h, and stimulated with human VEGF
(R&D Diagnostics) in EBM-2, 0.5% FBS for an additional 24 h.
[3H]Thymidine was added during the last 3 h of incubation of
the cells with VEGF (final concentration 1 Ci/ml), the cells
were washed to remove unincorporated [3H]thymidine and
harvested, and the incorporated radioactivity was quantified as
described (49). Proliferation of mouse LMVECs was measured
using the BrdU incorporation assay as described (50) with sev-
eralmodifications; cells were plated in black 96-well plates with
clear bottoms, and Alexa488-conjugated secondary Ab was
used to detect bound anti-BrdU antibodies. Fluorescence was
measured using the SynergyTM 2 Multi-Detection Microplate
Reader (BioTek Instruments, Inc.) and analyzed using the
Gen5TM Microplate Data Collection & Analysis Software.
Electrophoretic Mobility Shift Assay (EMSA)
HEK293 cells were transfected with HHEX-FLAG in
pcDNA3.1 vector. Two days after transfection, cells were har-
vested, andnuclear extractswere prepared using theNucBuster
Protein Extraction kit (Novagen, Gibbstown, NJ). EMSA
reactions were performed using biotinylated double-stranded
oligonucleotide derived from VEGFR2 promoter, 5-ACCA-
GATTCAGCTTTTTAAACTACAATTATACTG-3, and the
LightShift chemiluminescence EMSAkit (Pierce, Rockford, IL),
as described (38). uPA or BSA (500 ng/reaction) was added to
the binding reaction where indicated.
VEGF R1 and R2 Promoters Reporter Assay
Promoter reporter assay was performed using co-transfec-
tion of 1.3 kb VEGFR2 promoter luciferase reporter in pGL3
vector (Promega) (VEGFR2-pGL3) and 1.2-kb VEGFR1-pGL3
(51), uPA/pcDNA3.1, and HHEX-FLAG/pcDNA3.1 in
EA.hy926 cells as described by us previously (51) with the
exception that HHEX-FLAG/pcDNA3.1 vector was used
instead of pMUG1-Myc-PRH, and pRL-CMV vector (Pro-
mega) was co-transfected together with VEGFR1-pGL3 or
VEGFR2-pGL3 to normalize transfection efficiency using a
Dual Luciferase reporter assay kit (Promega).
Quantitative Reverse Transcriptase-mediated PCR
K562 cells (1 107) were transfected with 10g of pMUG1-
PRH or pSIH-uPA and empty pMUG1 and pSIH plasmids for
48 h. RNA was produced according to standard protocols.
Quantitative PCR was performed in triplicate as described (51)
using the primers listed below, and the datawere analyzedusing
Rotorgene 6 software (Corbett Research; Rotorgene RG-3000).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as the internal control. Results for relative expression
ratios were calculated according to the efficiency calibrated
mathematical model.
The primers used were as follows: Vegfr-1 forward, 5-TGG-
CCATCACTAAGGAGCACTCC-3, and reverse, 5-GGAAC-
TGCTGATGGCCACTGTG-3; Vegfr-2 forward, 5-TTAGT-
GACCAACATGGAGTCGTG-3, and reverse, 5-TAGT-
AAAGCCCTTCTTGCTGTCC-3; and GAPDH forward, 5-
TGATGACATCAAGAAGGTGGTGAAG-3, and reverse,
5-TCCTTGGAGGCCATGTGGGCCAT-3.
Statistical Analysis
Differences between groups were compared using the one-
way analysis of variance statistical test. Statistical analyses were
performed using the EZAnalyse add-in toMicrosoft Excel soft-
ware. Significance was set at a p value of0.05.
Results
uPA Is Required to Induce Angiogenesis by VEGF in Vivo—To
further assesswhether uPA is involved inVEGF-induced angio-
genesis (33, 52), we first asked if uPAmodulates VEGF-induced
capillary sprouting using aortic rings isolated from WT and
uPA/ mice. Aortae from WT mice embedded in Matrigel
developed sprouts in response to VEGF that were 3 times
longer those emanating from the aortae of uPA/ mice
(7.01 	 0.24 versus 2.32 	 0.15, respectively) (p  0.001) (Fig.
1A). The lengths of the sprouts developed from unstimulated
WT aortae were 1.43 times longer those from uPA/ mice
(p  0.001) (Fig. 1B), suggesting additional growth factors in
Matrigel that affect sprouting also depend on uPA, although
not to the same extent as VEGF.
uPA Potentiates VEGF-induced Microvascular Endothelial
Cell Proliferation, VEGF-induced Signaling, and Migration—
Angiogenesis requires that endothelial cells proliferate and
migrate. To examine the role of uPA in VEGF-induced EC pro-
liferation, mLMVECs from uPA/ and WT mice (53) were
incubated with VEGF. VEGF (10 ng/ml) induced a 3-fold
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increase in DNA synthesis in WTmLMVEC, whereas uPA/
mLMECs were almost completely non-responsive (Fig. 2A).
uPA/ mLMVECs were then transfected with a lentiviral
construct encoding mouse uPA (KO EC uPA LV) or with
empty lentiviral construct as a negative control (KO EC con
LV). Transfected cells were then stimulated with 5–25 nM
mouse VEGF for 18 h. KO EC uPA LV showed significantly
greater proliferation in response to VEGF than did KO EC
con LV cells (p 0.001) (Fig. 2B). Erk1,2 and PI3K-Akt-S6K
pathways are activated in endothelial cells stimulated by
VEGF (54–56) and have been implicated in mediating pro-
liferative responses in endothelium (57, 58) and in other cell
types (for review, see Ref. 59). VEGF induced sustained phos-
phorylation of Erk1,2 and the S6 ribosomal subunit (the sub-
strate of p70 S6 kinase, one of the effectors of the PI3K/Akt/
mTOR pathway; Ref. 60) in KO EC uPA LV within 2 min,
whereas either delayed phosphorylation of Erk1,2 (after 10
min of stimulation) or almost no S6 ribosomal subunit phos-
phorylation was seen in the KO EC con LV cells (Fig. 2C).
uPA also potentiated the proliferative response of human
LMVECs to VEGF (Fig. 2D).
We also comparedmigration ofmLMVEC isolated fromWT
and uPA/mice in response to VEGF. UnstimulatedWT and
uPA/ cells showed little or no migration through the porous
membrane (Fig. 3A). When stimulated with VEGF (25 ng/ml),
the migration response ofWTmLMVECwas3 times greater
than uPA/ LMVEC.
We then utilized an in vitro endothelial tube formation assay
to compare angiogenic activity ofWT and uPA/mLMVECs.
Although WT mLMVEC formed branching endothelial tubes,
uPA/mLMVEC formed clusters with few branches (Fig. 3B).
Time-lapse videomicroscopy revealed that random migration
of uPA/mLMVEC was slower than WT cells, and although
there was some evidence of elongation, the intercellular con-
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FIGURE 1.Vascular response to VEGF inWT and uPAKO (uPA/) mice. A, sprouting from the aortae ofWT or uPA/mice. Sproutingwas stimulatedwith
VEGF (5 ng/ml) in EGM-2medium (VEGF-depleted EGM-2medium served as a negative control). Representative images from 6 experiments under each of the
conditions are shown taken at day 7 post embedding of the vessel rings intoMatrigel. B, bar graph showing the length of sprouts (mean	 S.E.) from the aortae
ofWTor uPA/mice after stimulationwith VEGF (100 ng/ml). Results are representative of two independent experiments. *, p 0.05 for untreatedWT versus
uPA/ samples. **, p 0.001 for untreated WT versus VEGF-treated WT samples.
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nections were unstable (supplemental Movie 1). In contrast,
cells isolated from the WT mice readily formed tubular net-
work structures (supplement Movie 2).
uPA Translocates to the Nucleus of Endothelial Cells—uPA is
secreted as a scuPA (61, 62) that is able to bind uPAR (12) and
other receptors (14, 63) and can be converted into a two-chain
active enzyme by plasmin and some other proteases (64). We
previously reported that scuPA, but not two-chain uPA (tcuPA)
or a kringle-deficient uPA mutant (K-scuPA) (See Fig. 4A for
schematic representation of uPA variants), translocates rapidly
to the nuclei of diverse types of proliferating cells in a kringle-
dependent, uPAR-independent, manner (37). To determine
which scuPA variants translocated to the nuclei of human
LMVECs, WT-scuPA, GFD-scuPA, and K-scuPA were
radiolabeled with Na125I and incubated with hLMVECs for 1 h.
Exogenously added recombinant 125I-scuPA and 125I-GFD-
scuPA, but not 125I-K-scuPA, translocated to the nuclei of
proliferating hLMVECs (Fig. 4B). Fig. 4C shows the subcellular
distribution and immunofluorescence labeling of exogenously
added unlabeled scuPA, GFD-scuPA variant, that does not
bind uPAR (37, 42) but retains the kringle and translocates to
the nuclei of endothelial cells andK-scuPA variant. Untreated
hLMVECs are shown in the right panel. These data confirm
that uPAR is not essential for nuclear translocation of the krin-
gle-containing WT uPA or its variant in lung microvascular
endothelial cells.
To assess the relevance of this observation, we next asked
whether endogenous uPA is present within the nuclei of endo-
thelial cells in situ. Using confocal microscopy, we found that
uPA is present within the nuclei of endothelial cells (marked by
closed arrowheads) lining angiogenic vessels as well as within
the nuclei of tumor cells (not shown) in a specimen of non-
small lung carcinoma (Fig. 5, A and B). Not all nuclei stain for
uPA, even in cells that express cytoplasmic or cell surface uPA.
This suggests that the appearance of uPA within the nucleus
might be under spatial or cell cycle control.
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FIGURE 2. Stimulation of mitogenesis in endothelial cells by VEGF-A requires uPA. A, DNA synthesis in response to VEGF in LMVECs isolated fromWT or
uPA/mice. Endothelial cells were plated in 96-well plates, cultured for 24 h in completemedium, starved in 1% FBS/EBM for 24 h, and then stimulated with
VEGF (25 ng/ml) for an additional 24 h. DNA synthesis was assessed bymeasuring incorporation or 5-ethynyl-2-deoxyuridine. y axes denote -fold stimulation
of DNA synthesis in response to VEGF relative to untreated cells (1-fold). The results, representative of one of three independent experiments performed in
triplicate, are shown as the mean 	 S.E. B, re-expression of uPA in uPA/ endothelial cells restored DNA synthesis in response to VEGF. uPA/ LMVEC
transfected eitherwith “empty” (con) LV or uPA-bearing LVswere plated in 96-well plates, cultured, and serum-deprived as in Panel A. VEGFwas added for 24 h
at the indicated concentrations, andDNA synthesiswasmeasured as in panel A. x axes denote concentrations of VEGF in ng/ml. y axes denote -fold stimulation
of DNA synthesis in response to VEGF relative to untreated cells (1-fold). Data from three independent experiments performed in triplicate are shown as the
mean	 S.E. * denotes p 0.05, ** denotes p 0. 001. C, re-expression of uPA in uPA/ endothelial cells amplified VEGF-induced signaling. uPA/ LMVEC
were transfected with empty (con) LV or uPA-bearing LV, starved overnight, and lysed at the indicated times after stimulation with VEGF (10 ng/ml). Western
blot analysis shows the time course of ERK1/2 and ribosomal S6 unit phosphorylation, which reflects activation of the PI3k/Akt/mTOR/S6 Kinase (S6K) pathway
(60). Anti-GAPDHwasused to ensure equal protein loading. The illustratedblots are representative of three independent experiments.D, uPApotentiatesDNA
synthesis in response to VEGF in hLMVECs. hLMVECwere plated in 48-well plates, cultured for 24 h in completemedium, starved in 1% FBS/EBM for 24 h in the
absence or presence of 20 nM uPA, and stimulatedwith VEGF at the indicated concentrations for an additional 24 h. DNA synthesis was assessed bymeasuring
[3H]thymidine incorporation into DNA. Data are representative of three experiments performed in triplicate are shown as mean	 S.E.
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uPAs That Are Capable of Translocation to Nuclei Up-regu-
late Expression of VEGFR1 and VEGFR2—Binding of VEGF-A
to VEGFR1 (Flt1) and VEGFR2 (KDR) has been implicated in
pro-mitogenic signaling in endothelial cells (for review, see Ref.
65). Having observed that VEGF induces a greater proliferative
response in uPA-expressing ECs, we next asked whether these
cells express higher levels of VEGFR1 and VEGFR2 and
whether intranuclear uPA is responsible for this phenotype. To
do so, we first compared the expression levels of VEGF recep-
tors in mouse LMVECs isolated from WT and uPA/ mice
and in uPA/ LMVECs transfected with LV vectors encoding
mouse WT or K-uPA (KO EC uPA LV and KO EC K-uPA
LV, respectively) or empty vector as the negative control (KO
EC con LV). WT LMVEC and KO EC uPA LV cells showed
higher expression levels of VEGFR1 and VEGFR2 than their
uPA/ counterparts or KO EC K-uPA LV cells (Fig. 6A),
which expressed a variant that is unable to translocate to the
nucleus (Fig. 4B andRef. 37). The addition of recombinantWT-
scuPA and GFD-scuPA, but not K-scuPA (10 nM), to hLM-
VECs for 24 h up-regulated VEGFR1 and VEGFR2 expression
(Fig. 6B). Together, these data suggest that only uPA variants
capable of translocation to nuclei up-regulate expression of
VEGFR1 and VEGFR2.
Nuclear uPA in EC Enhances VEGF-induced Angiogenic
Responsiveness—To relate increased expression of VEGF
receptors in response to intranuclear uPA to the angiogenic
potential of ECs, we re-expressed either WT-uPA or K-uPA
variants in uPA/mLMVECs and studied theirmigration and
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FIGURE 3. ECmigration and in vitro tube formation in response to VEGF requires uPA. A, migration of lungmicrovascular ECs isolated fromWT or uPA/
mice in response to VEGF. LMVECs were starved in EBM-2/0.5% FBS for 24 h, detached with trypsin/EDTA, washed in starvation medium, and resuspended in
the same medium. Cell suspensions were added inside FluoroblokTM transwells, which were placed in 24-well plates containing either starvation medium or
the samemediumsupplementedwith 25ng/ml VEGF. Transwellswere incubatedwith calceinAMandHoechst to visualizemigrating cells and then fixed. Cells
were allowed to migrate for 18 h and were then photographed with a 4 objective using the EVOS FL Auto Imaging System microscope. Cells within the
imaged field were counted. Each condition was set up in three wells, and three images were taken at different sites within each transwell. Typical images for
each condition are shown. The bar graph on the right shows themean	 S.E. cell numbers permicroscopic field ofWTor uPA/ cells thatmigrated in response
to VEGF. Few cellsmigrated in starvationmedium (two-three permicroscopic field) and, therefore, do not appear on the graph. *, p 0.001. B, tubular network
formationbyWTanduPA/ ECs in response toVEGF.WTanduPA/ ECswere allowed to adhere andmigratewithin a 24-well plate coatedwithMatrigel. The
endothelial cell network was visualized by loading the cells with Calcein AM dye (4 g/ml), and photographs were taken using an EVOS FL Auto Imaging
Systemmicroscope. Typical images for each condition are shownon the left. Total length of the tubeswas enumerated using the ImageJ software. *, p 0.001
(right).
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in vitro tube formation in response to VEGF. Fig. 6C shows that
re-expression ofWT-uPA caused a 2.48-fold increase inmigra-
tion of uPA/ mLMVECs (p  0.01), whereas expression of
K-uPA caused only a 1.37-fold (although significant, p 0.01)
increase inmigration compared with uPA/mLMVEC trans-
fected with empty lentivirus. K-uPA-transfected uPA/
mLMVECs, like cells transfected with empty vector, formed
cell clusters in the presence ofVEGF in lieu of a tubular network
(Fig. 6, D and E), whereas WT-uPA-expressing cells formed
tubular network structures similar to WT mouse mLMVECs
(Fig. 6, D and E, with reference to Fig. 3B).
We then asked if the capacity of WT-uPA to translocate to
the nucleus is involved in aortic sprouting. Aortic rings isolated
from uPA/ mice were transfected with WT-uPA, K-uPA,
and empty control pWPXL-based LVs immediately after iso-
lation and embedded in Matrigel 24 h later. The parental
pWPXL vector-based LV, which encodes GFP, was used to
elucidate transfection efficiency of vessel ring tissues by LV.
Fig. 7A shows that GFP was effectively delivered by LV. RT
PCR analysis of the vessel rings transduced with the empty
and WT-uPA- or K-uPA-encoding LVs confirmed trans-
fection (Fig. 7B). VEGF induced intense sprouting from the
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FIGURE 4. A, Schematic representation of uPA variants and their relevant properties. WT, wild type; tcuPA, two-chain uPA; K, kringle; PD, protease domain,
GFD-uPA, GFD-deficient uPA; K-uPA, Kringle-deficient uPA; LMW-uPA, low molecular weight (LMW) uPA missing the GFD and Kringle domains; ATF-uPA,
N-terminal fragment of uPA consisting of the GFD and the kringle. B, nuclear translocation of uPA in hMLVEC depends on its kringle domain. Recombinant
WT-uPA and K-uPA, isotopically labeled with Na125I as described (37), were incubated with hMVLEC for 1 h. Cells were then washed to remove unbound
radioactive proteins and fractionated, and membrane-, cytoplasm- and nucleus-associated uPAs were quantified (37). Results are presented as the amount
(fmol) of each protein found in each cellular fraction (membrane-bound, cytoplasmic, and nuclear) obtained from106 cells. All experimentswere performed in
triplicate. *, p 0.05. C, nuclear localization of exogenously added WT-uPA, GFD-uPA, and K-uPA in hLMVEC (left panel). Cells growing exponentially on
8-well chamber slides were incubatedwith recombinantWT-uPA orGFD-uPA orK-uPA (10 nM) for 1 h, washed, and fixed inMeOH. uPAwas detected using
immunofluorescence as described under “Experimental Procedures” and in Stepanova et al. (37) with anti-uPA rabbit polyclonal antibodies and Alexa 488-
conjugated secondary anti-rabbit antibodies. Nuclei were counterstained with DAPI and pseudo-colored in red. Green denotes positive staining for uPA.
Nuclear localization of anti-uPA antibody-positive staining was quantified using Zeiss LSM 5 Image software. The white arrow (merge panels) was used to
denote the profile quantified by the LSM 5 Image software. A graphic representation of the quantitative analysis of this profile for each treatment is shown on
the bottom of the collage. The right panel shows staining obtained when control rabbit Ig (R Ig) was used as a negative control. Scale bar, 20 m.
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aortae expressing WT-uPA, whereas significantly less
sprouting was observed from the rings expressing K-uPA
or transfected with empty LV (Fig. 7, C and D). These data
indicate that K-uPA, which does not translocate to the
nucleus, are unable to fully restore angiogenic capacity to
uPA/ ECs in response to VEGF in contrast to WT-uPA,
which invests uPA/ ECs with a responsiveness compara-
ble to ECs isolated from WT mice (Fig. 1).
Intranuclear uPA Binds to HHEX/PRH Transcription Factor
and Abolishes Repression of vegfr1 and vegfr2 Promoters—We
recently reported that uPA binds several homeobox transcrip-
tion factors, including HOXA5 and Hey (38), that might be
involved in regulating VEGFR1 and VEGFR2 expression (39,
40). Using a transcription factor protein-protein microarray,
we found that uPA also binds to HHEX/PRH transcription fac-
tor (Fig. 8A).We previously reported that HHEX/PRH binds to
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FIGURE 5.Nuclear localization of uPA in situ. A, staining of tissue specimens for uPA and SM -actin. Paraffin-embedded sections of non-small human lung
carcinoma tissue were stained with anti-uPA monoclonal antibody (top panels) or with mouse IgG1 (m Ig) as a negative control (bottom panels), depicted in
green. Nuclei were counterstained with SYTO-6 (pseudo-colored in red). Smooth muscle a-actin was stained using Cy3-conjugated mouse monoclonal anti-
body to localize vessels and airways in tissue specimen (pseudocolored in blue). Examples of nuclear localization of uPA in vascular ECs are denoted bywhite
arrowheads. Immunostaining was analyzed using a confocal microscope ZEISS LSM 510 using a 40 objective. Scale bar, 20 m. B, quantitation of nuclear
localization of uPA. Nuclear localization of anti-uPA antibodywas quantified using Zeiss LSM5 Imaging software. Thewhite arrow (top image) is used to denote
the profile quantified by the LSM 5 Image software. A graphic representation of the quantitative analysis of this profile is shown on the bottom. C, low
magnification ImagesofA. Images areof the samearea takenusing the10objective. Theupper panel shows staining foruPA, smoothmuscle actin, andnuclei.
The lower panel shows staining using control rabbit Ig instead of anti-uPA antibodies (negative control). Scale bar, 200 m. Squares indicate areas taken for
magnification.PanelD, immunohistochemical stainingof the tissue sections for the endothelial cellmarker vonWillebrand factor. The slide stained for uPAwas
dismounted and used togetherwith intact parallel sections for immunostaining using rabbit polyclonal anti-vonWillebrand factor antibody to assesswhether
uPA was detected in the nuclei of endothelial cells of the vessels within tumor tissue as described under “Experimental Procedures.” Total rabbit Ig served as
a negative control. The brown color (top andmiddle panels) denotes vascular endothelial cells; nuclei are depicted in blue. Images of the same vessel as in A,
marked by black arrowhead in the section previously stained for uPA and in the fresh serial section, are shown in the top andmiddle panels, respectively. The
bottom panel represents a negative control using a fresh serial section. Images were taken using the EVOS FL Auto Imaging system using a 40 objective.
Scale bar
 100 m.
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the promoter regions of the VEGFR1 and VEGFR-2 genes and
represses their transcription (51). Therefore, we next tested the
hypothesis that intranuclear uPAde-represses vegfr1 and vegfr2
promoters by binding to HHEX. In support of this hypothesis,
uPA co-immunoprecipitated withHHEX/PRHwhen both pro-
teins were overexpressed in 293HEK cells (Fig. 8B). As quies-
cent ECs typically express low levels of uPA, to determine if
uPA co-immunoprecipitates with endogenous HHEX, we pre-
incubated hMVECwith recombinant scuPA. HHEX co-immu-
noprecipitated with uPA from scuPA-treated hMVECs (Fig.
8C). We then used a series of uPA domain deletion mutants
listed in Fig. 4A to determine which domain(s) is required for
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VEGF. A, WTmouse LMVEC and uPA-LV-KO-LMVEC but notK-uPA-LV-KO-LMVEC express higher levels of VEGFR1 and VEGFR2. Lungmicrovascular endothe-
lial cells isolated from WT or uPA/ mice (uPA/ LMVEC) or uPA/ LMVEC transfected either with empty LV, full-length mouse uPA-encoding LV, or
K-uPA-encoding LV were lysed. The lysates were subjected to SDS-PAGE andWestern blot analysis. Membranes were probedwith anti-VEGFR1 and VEGFR2
antibodies. Membranes probed with the anti-GAPDH antibodies served as the loading control. The illustrated blots are representative of three independent
experiments. B, uPA variants capable of nuclear translocation induce VEGFR1 and VEGFR2 expression in human lungmicrovascular endothelial cells. hMVECs
wereplated in EBM-2mediumsupplementedwith 5%FBS andgrowth supplements, starved in EBM-2/1%FBS for 24h, and stimulatedwith 20nM recombinant
full-length human uPA (WT-uPA), GFD-deficient uPA variant (GFD-uPA), or Kringle-deficient uPA (K-uPA). VEGFR1, VEGFR2, and GAPDH expression was
analyzed as above. The blots shown are representative of three independent experiments. C, re-expression of WT-uPA but not K-uPA in EC isolated from
uPA/mice significantly increasesmigration in response VEGF. ECs isolated from uPA/mice were transfectedwith LVs encoding eithermouseWT-uPA or
the K-uPA variant. Cell migration was assayed as described in Fig. 3A. The bar graph shows cell numbers (mean	 S.E.) per microscopic field for uPA/ ECs
transfected with empty, WT-uPA, or K-uPA-encoding LV migrated in response to VEGF. Few cells migrated in starvation medium (2–3 cells per microscopic
field), and therefore, the numbers do not appear on the graph. *, p 0.01 for values for KO con LV cells versus values for KO DK-uPA LV cells , **, p 0.01 for
values for KOWTuPA cells versus values for KO con LV.D, formation of tubular network in response to VEGFbyuPA/ ECs inwhichWT-uPAorK-uPA variants
were re-expressed. ECs were set up for in vitro tube formation as in Fig. 3B. Cells were incubated for 22 h and photographed at the end of incubation using the
EVOSFLAuto Imaging System. Threewellswere set upper each cell type, and three locationswithin eachwellwere photographed. Typical pictures for uPA/
EC transfectedwith empty LV (KO EC con LV), LV encodingmouseWT-uPA (KO EC uPA LV), andmouseK-uPA (KO ECK-uPA LV) are presented. Images were
analyzedusing ImageJ software. Thebar graph showsquantitative analysis of the total tube lengthswithin the tubular network (mean	S.E.). *,p0.01, values
for KO con LV cells versus KO uPA LV Cells, #, p 0.001, for values for KO uPA LV cells versus KODK-uPA LV cells. E, typical images for each condition quantified
in D. Inset, RT PCR analysis of the total RNA samples isolated from the empty and WT-uPA- and K-uPA-LV-transfected uPA/ LMVECs.
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binding to HHEX. uPA variants were immobilized onto the
wells of a 96-well plate. Immobilized uPAs were then incubated
with nuclear extracts from 293 HEK cells transfected with
HHEX-FLAG/pcDNA3 plasmid, which encodes full-length
HHEX possessing a FLAG tag at the C terminus. WT-scuPA
and GFD-scuPA bound HHEX, in contrast to ATF, which
lacks the proteolytic domain, and lowmolecular weight-uPA or
K-scuPA, which lacks the kringle (Fig. 8D). This result indi-
cates that both the kringle and the C-terminal proteolytic
domain are necessary for binding to HHEX.
To determine whether uPA induces expression of VEGFR1
and VEGFR2 by interfering with the repressor function of
HHEX, we used the K562 cell line. K562 cells express low levels
of endogenous uPA, and they express both VEGFR1 and
VEGFR2, which can be suppressed by ectopic expression of
HHEX (51). K562 cells were co-transfected with the HHEX-
and/or uPA-encoding vectors alone or in combination, and
VEGFR1 and VEGFR2 mRNA levels were measured. The
results shown in Table 1 demonstrate that overexpression of
HHEX suppresses both VEGFR1 and VEGFR2 mRNA levels.
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FIGURE 7. Sprouting in response to VEGF from the aortae of uPA/mice transfected with empty, WT-uPA, andK-uPA LVs. A, aortic ring transfected
with control pWPXL vector-based LV, which encodes GFP. Aortic rings isolated from uPA/mice were incubated with pWPXL-based LV at 100multiplicity of
infection in EBM-2 medium for 24 h. The rings were then embedded in Matrigel and layered with EBM-2 medium containing VEGF. On day 8, sequences of
imageswere taken in various z sections at 3.3-mintervals to visualizeGFP-expressing cellswithin the vessel, whichwere then subjected to three-dimensional
reconstitution using ImageJ software. A virtual three-dimensional image of the GFP-expressing cells within the aortic ring is shown. Color-coded sequential
position of each z-section is indicated on the scale on the left panel. B, RT PCR analysis of the total RNA samples isolated from the empty-, WT-uPA- and
K-uPA-LV-transfected aortic rings. C, sprouting from the aortae of uPA/ mice transfected with the empty-, WT-uPA-, and K-uPA- LVs. Sprouting was
stimulated with VEGF (100 ng/ml) in EBM-2 medium. Representative images from five-six experiments under each of the conditions are shown. D, bar graph
showingmean	S.E. area (top) or length (bottom) of sprouts fromaortaeofWToruPA/miceafter stimulationwithVEGF. **,p0.001 for valueuPALV versus
value for KO con LV; *, p 0.001 for value uPA LV versus value for KO DK-uPA LV; #, p 0.01 for value con LV versus value for KO DK-uPA LV.
Nuclear uPA Regulates Expression of VEGF Receptors
15040 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 29•JULY 15, 2016
 at The U
niversity of Birm
ingham
 on Septem
ber 13, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Ectopic expression of uPA alone did not significantly change
VEGFR1 or VEGFR2 expression, providing further evidence
that uPA does not directly affect transcription of the VEGFR1
and VEGFR2 promoters. However, co-expression of uPA
together with HHEX reversed HHEX-mediated repression of
VEGFR1 andVEGFR2. These data suggest that binding of uPA to
HHEX inhibits binding of the transcription factor to its target
DNAsequence.To examine this possibility inmoredetail, weper-
formedanEMSAusing vegfr2promoter-deriveddouble-stranded
oligonucleotide that contained a HHEX consensus region (see
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FIGURE 8. Functional consequences of uPA binding to HHEX. A, TranSignal Transcription factor Protein Array. Array Membranes (Panomics, Version I)
spotted in duplicatewith proteins expressed from full-length transcription factor cDNAswere incubatedwith scuPA (10 nM) for 2 h. Bound scuPAwas detected
with rabbit anti-uPA polyclonal antibodies, HRP-conjugated secondary goat anti-rabbit antibodies, and chemiluminescence substrate. B, co-immunoprecipi-
tation (co-IP) of uPAandHHEX from293HEK cells ectopically expressingHHEX-FLAGanduPA.HEK293 cellswere transfectedwithHHEX-FLAG inpcDNA3.1 and
uPA/pcDNA3.1 vectors. Two days later, cells were harvested, and nuclear extracts were prepared using the NucBuster protein extraction kit (Novagen). uPA or
HHEXwas immunoprecipitated usingmousemonoclonal anti-uPA or anti-FLAG antibodies immobilized on agarose beads. Normal mouse Ig immobilized on
agarose beads was used as the negative control. Immune complexes were analyzed by Western blot (WB) using anti-uPA rabbit polyclonal antibodies and
HRP-conjugated anti-FLAG mouse monoclonal antibodies. C, co-immunoprecipitation of uPA and HHEX from the nuclear extracts of human scuPA-treated
human LMVECs. uPA and HHEXwere co-immunoprecipitated from the nuclear extracts usingmousemonoclonal anti-uPA and anti-HHEX antibodies, respec-
tively. Normal mouse Ig immobilized on agarose beads was used as the negative control. Immune complexes were analyzed by Western blot using anti-uPA
rabbit polyclonal antibodies and anti-HHEX rabbit polyclonal antibody.D, binding of HHEX to recombinant uPA variants. Recombinant uPA variants (33 nM in
PBS) or BSA (1%) as the negative control were immobilized in 96-well plates in triplicate and incubatedwith nuclear extract fromHEK293 cells transfectedwith
pcDNA 3.1/HHEX-FLAG. Bound HHEX-FLAG was detected using an anti-HHEX polyclonal antibody/HRP-anti-rabbit antibody sandwich ELISA. Optical density
was readat450nm(OD450). yaxesdenotenormalizedOD450obtainedby subtracting theOD450measured inBSA-coatedwells fromtheOD450measured inwells
coatedwith uPA variants. E, uPA inhibits binding of HHEX to the target DNA sequence. HEK 293 cells were transfectedwith HHEX-FLAG in pcDNA3.1. Two days
later, cells were harvested, and nuclear extracts were prepared. EMSA reactions were performed using biotinylated double-stranded HHEX specific oligonu-
cleotides and corresponding unlabeled oligonucleotide. 1, no nuclear extracts (NE); 2, NE in presence of 50 excess unlabeled HHEX-specific oligonucleo-
tide; 3,NE alone; 4,NE in the presence of BSA; 5, scuPA (500 ng); 6,NE scuPA (500 ng); 7, scuPA in the presence of anti-uPA antibody; 8,NE
mouse IgG; 9,NE anti-FLAGmousemonoclonal antibody; 10,NE in thepresence of irrelevant unlabeled oligonucleotides. S, probe shift causedbyHHEX
overexpression. SS. probe supershift causedbyHHEX-boundanti-FLAGantibody. F, VEGFR1 andVEGFR2promoter luciferase reporter assay. HumanVEGFR1or
VEGFR2promoter-driven luciferase reporter pGL3 (51) vectorswere co-transfected in EA.hy926 cellswith uPA- andHHEX-encodingpcDNA3.1 vectors alone or
in combination. Luciferase activity was measured at 24 h using a Dual Luciferase Reporter assay kit (Promega). Outcomes were normalized to the activity of
co-transfected renilla luciferase-encoding pRL-CMV vector (Promega).
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“Experimental Procedures”). The data show that WT scuPA did
not bind directly to the HHEX DNA consensus sequence, but it
did inhibit binding of HHEX to its DNA target site (Fig. 8E).
These hypotheses were further supported by the results of
the VEGFR1 and VEGFR2 promoter luciferase reporter assay.
Expression of HHEX resulted in a 3.49- and 2.68-fold repres-
sion of VEGFR1 and VEGFR2 promoter activities, respectively,
whereas co-expression of HHEX with uPA partially but signif-
icantly reversed inhibition of VEGFR1 and VEGFR2 promoter
activity by HHEX (Fig. 8F). These results provide additional
support for the hypothesis that binding uPA to HHEX leads to
de-repression of the VEGFR1 and VEGFR2 promoters.
Discussion
VEGF and uPAplay prominent roles in angiogenesis (59, 66).
VEGF165 induces endothelial cell motility, invasion, and prolif-
eration by binding to specific receptors, VEGFR1 (Flt-1) and
VEGFR2 (KDR) (59). Binding of VEGF to these receptors up-
regulates the expression of uPA and generates plasmin that
converts catalytically inactive scuPA into enzymatically active
tcuPA (67). tcuPA proteolyzes extracellular matrices and
induces intracellular signal transduction through autocrine and
paracrine pathways that promote endothelial cell proliferation
and migration (for review, see Ref. 66). In this manuscript we
describe an additional mechanism by which uPA promotes
angiogenesis, i.e. via transcriptional up-regulation of VEGFR1
and VEGFR2 expression.
Our findings show that proliferation of human and mouse
microvascular endothelial cells in response toVEGF-A requires
the presence of uPA in the nucleus where it binds to the tran-
scription factor HHEX. Binding of uPA of HHEX interferes
with transcriptional repression of the vegfr1 and vegfr2 promot-
ers leading to up-regulation of receptor expression.
Nuclear translocation of uPA in endothelial cells does not
require uPAR, as both full-length uPA and a variant lacking the
uPAR binding GFD are both able to translocate to cell nuclei
(37) (Fig. 4C) and up-regulate both VEGF receptors (Fig. 6B).
Rather, translocation of uPA to the nucleus and up-regulation
of expression of VEGF receptors depends on its kringle domain
(37) (Figs. 4B and 6A). We previously reported that nuclear
translocation of uPA is mediated by nucleolin (37), a nucleocy-
toplasmic shuttle protein that transports diverse proteins from
the cytoplasm to the nucleus (68). Nucleolin is located on the
external plasma membrane of angiogenic endothelial lining
tumor vessels but not on neighboring endothelium lining
non-proliferating host vessels (69), but how its appearance
on cell surfaces is regulated is unknown. Blockade of cell
surface nucleolin with a specific pseudopeptide reduces
tumor progression in mouse models of cancer (70, 71).
Therefore, the preferential translocation of nucleolin onto
the surface of angiogenic endothelial cells may promote
nuclear translocation of uPA and lead to de-repression of
VEGFRs expression.
To find the intranuclear target for uPA responsible for its
pro-angiogenic activity, we profiled uPA-binding transcription
factors using a transcription factor protein-proteinmicroarray.
We found that uPA binds transcription factor HHEX, also
referred to as proline-rich homeodomain protein (PRH) tran-
scription factor, which has been identified by us previously as a
transcriptional repressor of the vegfr1 and vegfr2 promoters
(51).
We chose one of the potential HHEX DNA sequences
derived from the vegfr2 promoter to help elucidate the mecha-
nism by which uPA modulates the DNA binding capacity of
HHEX. Our data show that uPA does not bind directly to this
dsDNA oligonucleotide. Rather, uPA binds to HHEX (Fig. 8,
A–C), inhibiting its capacity to dock onto its target DNA
sequence (Fig. 8E). Our data also demonstrate that overexpres-
sion of HHEX/PRH reduces VEGFR1 and VEGFR2 mRNA
expression and that co-expression of HHEX and uPA prevents
repression ofVEGFR1 andVEGFR2byHHEX/PRH.Therefore,
our data suggest that in quiescent endothelial cells HHEX
represses expression of VEGF receptors. In contrast, overex-
pression of uPA in response to VEGF (67) or other mediators
released by tumors or surrounding stroma (31, 72) as well as
release of uPA by tumor or stromal cells (73, 74)may “sensitize”
endothelial cells to pro-angiogenic stimuli through uPA-medi-
ated de-repression of VEGFRs promoters, thereby promoting
angiogenesis even in the absence of a significant change in
VEGF expression per se.
uPA might also regulate angiogenesis by binding to other
transcription factors that activate or repress additional genes.
For example, we recently reported that uPA promotes survival
of pancreatic cancer cells in part by binding to the homeobox
transcription factor HOXA5 leading to down-regulation of p53
expression (38). Sustained expression of HOXA5 leads to
down-regulation of many pro-angiogenic genes including
vegfr2, ephrin A1, Hif1, and cox-2 (39). Additional studies are
needed to determine whether binding of uPA to HOXA5 and
TABLE 1
Vegfr-1, andVegfr-2mRNA levels in K562 cells 48 hr after co-transfectionwith pMUG1 (empty vector), pMUG1-Myc-PRH, pSIH (empty vector), or
pSIH-uPA
Levels ofmRNAwere determined by quantitative reverse transcriptase-PCRusing specific primers and compared toGAPDHmRNA.Values are shown as -fold change over
control values obtained (means and S.E.) in a sample co-transfected with pMUG1 (empty vector) and pSIH (empty vector) (n
 3).
Expression vector(s)
vegfr-1 vegfr-2 uPA PRH
Mean -fold
change S.E.
Mean -fold
change S.E.
Mean -fold
change S.E.
Mean -fold
change S.E.
pmug1-emptypSIH3-empty 1 1 1 1
pmug1-PRHpSIH3-empty 0.759a 0.011 0.623b 0.07 0.710 0.21 728.09 299.74
pmug1-emptypSIH3-uPA 1.499 0.122 1.569 0.19 549.227 524, 01 3.35 0.946
pmug1-PRHpSIH3-uPA 2.331 1.13 1.414 0.62 183.469 69.21 181.95 30.34
a p 0.005 relative to control (pmug1-emptypSIH-empty).
b p 0.005 relative to control (pmug1-emptypSIH-empty).
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other homeobox transcription factors in endothelial cells pro-
motes angiogenesis during physiological and pathological
angiogenesis by inducing an angiogenic switch through coordi-
nate up-regulation and/or down-regulation of genes involved
in endothelial cell proliferation, adhesion, andmigration. These
data also suggest that targeting nuclear transport of uPA
through its kringle or the motif that mediates its binding to
transcription factors might provide novel means to control
aberrant angiogenesis with minimal impact on healthy
vasculature.
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